Aralez Pharmaceuticals Inc (ARLZ):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8159)
◆英語タイトル:Aralez Pharmaceuticals Inc (ARLZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8159
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Aralez Pharmaceuticals Inc (Aralez Pharma) is a pharmaceutical company that develops and commercializes therapeutic drugs. The company offers products in the fields of cardiovascular diseases, pain management, dermatology, gastrointestinal, and other areas. Its pain management products include cambia, vimovo, treximet, durela, fiorinal and fiorinal C, among others. Aralez Pharma also offers non prescription products for women’s health. Aralez Pharma’s others products include blexten, moviprep, mutaflor, normacol, pegalax, proferrin, resultz, soriatane, and others. The company has operations in New Jersey, the US; and Dublin, Ireland. Aralez Pharma is headquartered in Mississauga, Ontario, Canada.

Aralez Pharmaceuticals Inc (ARLZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aralez Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aralez Pharma Acquires US Rights to Toprol-XL and Authorized Generic from AstraZeneca 13
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 15
Venture Financing 16
Aralez Pharma Secures USD75 Million in Venture Debt Financing 16
Private Equity 17
Aralez Pharma to Sell its Toprol XL Franchise 17
Partnerships 18
Lannett Enters into Distribution Agreement with Aralez Pharma 18
Biohit Enters Into Distribution Agreement With Medical Futures 19
Merger 20
Pozen and Tribute Pharma Merges 20
Licensing Agreements 21
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400 21
Equity Offering 22
Aralez Pharma Plans to Raise up to USD100 Million in Public Offering of Securities 22
Aralez Pharma Raises USD45 Million in Private Placement of Shares 23
Pozen Plans Public Offering of Shares for USD57.5 Million 25
Asset Transactions 26
Nuvo Pharma to Acquire Pharma Business from Aralez Pharma for USD110 Million 26
Acquisition 28
Tribute Pharma Acquires Medical Futures for USD20 Million 28
Aralez Pharmaceuticals Inc – Key Competitors 29
Aralez Pharmaceuticals Inc – Key Employees 30
Aralez Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Strategy And Business Planning 33
Aug 13, 2018: Aralez Pharmaceuticals divests core businesses for $250m 33
May 08, 2018: Aralez Announces New Strategic Direction 34
Financial Announcements 35
May 08, 2018: Aralez Announces First Quarter 2018 Financial Results 35
Mar 13, 2018: Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results 37
Nov 09, 2017: Aralez Announces Third Quarter 2017 Financial Results 40
Aug 09, 2017: Aralez Reports Second Quarter 2017 Financial Results 42
May 09, 2017: Aralez Reports First Quarter 2017 Financial Results 44
Mar 13, 2017: Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results 47
Corporate Communications 50
Nov 30, 2017: Aralez Announces Departure of Chief Financial Officer 50
Jun 07, 2017: Aralez Announces Board Member Resignation 51
Apr 05, 2017: Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program 52
Legal and Regulatory 53
Aug 20, 2018: Nuvo Pharmaceuticals announces extension of exclusivity period with Aralez and Deerfield 53
Product News 54
02/16/2018: Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet by Company’s Subsidiary, Macoven Pharmaceuticals 54
02/03/2017: Pernix Therapeutics Provides Update on Arbitration 55
Product Approvals 56
Jan 09, 2017: Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aralez Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aralez Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aralez Pharma Acquires US Rights to Toprol-XL and Authorized Generic from AstraZeneca 13
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 15
Aralez Pharma Secures USD75 Million in Venture Debt Financing 16
Aralez Pharma to Sell its Toprol XL Franchise 17
Lannett Enters into Distribution Agreement with Aralez Pharma 18
Biohit Enters Into Distribution Agreement With Medical Futures 19
Pozen and Tribute Pharma Merges 20
Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400 21
Aralez Pharma Plans to Raise up to USD100 Million in Public Offering of Securities 22
Aralez Pharma Raises USD45 Million in Private Placement of Shares 23
Pozen Plans Public Offering of Shares for USD57.5 Million 25
Nuvo Pharma to Acquire Pharma Business from Aralez Pharma for USD110 Million 26
Tribute Pharma Acquires Medical Futures for USD20 Million 28
Aralez Pharmaceuticals Inc, Key Competitors 29
Aralez Pharmaceuticals Inc, Key Employees 30
Aralez Pharmaceuticals Inc, Other Locations 31
Aralez Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aralez Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Aralez Pharmaceuticals Inc (ARLZ):製薬・医療:M&Aディール及び事業提携情報(Aralez Pharmaceuticals Inc (ARLZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆